Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

SHC216V

Sigma-Aldrich

MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Transduction Particles

Targets no known genes from any species

Synonym(s):

MISSION®, MISSION® Control Transduction Particles, negative control, negative shRNA control, non-target control, non-target shRNA, non-target shRNA control, shRNA control

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41106609
NACRES:
NA.51

Quality Level

100
200

product line

MISSION®

concentration

≥1x106 VP/ml (via p24 assay)

shipped in

dry ice

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

General description

The MISSION® TRC2 pLKO.5-puro Non-Target shRNA Control Tranduction Particles contain an shRNA insert that does not target any known genes from any species, making it useful as a negative control in experiments using the MISSION® shRNA library clones. This allows one to examine the effect of transduction of a short-hairpin on gene expression and interpret the knockdown effect seen with shRNA clones. Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. The Non-Target shRNA Control Transduction Particles are provided as 200 uL at 1 x 106 TU/mL via p24 assay.
When conducting experiments using MISSION® shRNA clones, the proper controls should be a key element of your experimental design to allow for accurate interpretation of knockdown results. The MISSION Control Transduction Particles are a critical positive control to monitor transduction efficiency.
To see more application data, protocols, vector maps visit sigma.com/shrna.

Application

To see more application data, protocols, vector maps visit sigma.com/shrna.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation.
Pedroza M
Faseb Journal, 30(1), 129-140 (2016)
The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma.
Manier S
Leukemia, 31(4), 853-860 (2017)
Curtis A Clark et al.
Cancer research, 76(23), 6964-6974 (2016-09-28)
PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cells, but its
Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.
Lewis KM
Lung Cancer, 90(2), 182-190 (2015)
Katherine M Lewis et al.
Lung cancer (Amsterdam, Netherlands), 90(2), 182-190 (2015-09-28)
Lung cancer is the leading cause of cancer death in both men and women. Non-small cell lung cancer (NSCLC) has an overall 5-year survival rate of 15%. While aberrant STAT3 activation has previously been observed in NSCLC, the scope of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service